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1. Introduction
Considering the increasing role of protein therapeutics in the phar-
maceutical market, proven by the fact that currently most of the high
revenue drugs are monoclonal antibodies, Fc-fusion proteins and glyco-
protein based new modalities, their comprehensive characterization is
of high importance [1]. In most therapeutic mAbs this characterization
process means the analysis of the N-glycosylation present at the con-
served Asn297 site located of the CH2 domain in the Fc region of anti-
body based molecules. Generally, these N-glycans are deeply involved in
the biological activity, physicochemical properties and serum half-life of
a glycoproteins. Fc glycosylation in mAbs and Fc fusion proteins affect
their effector functions such as antibody-dependent cellular cytotoxic-
ity (ADCC) and complement-dependent cytotoxicity (CDC). Another im-
portant sugar residue dependent function of glycosylated biotherapeu-
tics can be the anti-inflammatory effect influenced by terminal sialy-
lation [2]. Clearance of mAbs are also affected by the type of glyco-
sylation they carry. For instance, it has been shown that the so called
G0 glycoform (asialo-, agalacto-, biantennary core fucosylated complex
N-glycan, also referred to as FA2 by the Oxford nomenclature [3]),
which contains no galactoses and therefore presents terminal N-acetyl-
glucosamines (GlcNAc), is bound by a C-type lectin, a mannose receptor,
thus, cleared by dendritic cells and macrophages [4,5]. Similarly, IgGs
bearing high mannose-type glycans exhibit reduced serum half-life [6].
These findings have strong implications in therapeutic antibody quality
control, suggesting that glycoforms should be carefully controlled, even
at low levels if immunogenic such as the α1-3 Gal or N-Glycolylneu-
raminic acid epitopes. In most instances, the above listed functions and
features are parts of the mode of drug action in relation to their safety
and clearance profile [7]. Therefore, detailed analysis of these glycans
provides important critical quality attribute (CQA) information.
Given its importance, regulatory guidelines require the characteri-
zation and monitoring of N-glycans since glycoproteins always display
a heterogeneous set of glycans depending on the genetics of the host
cell line as well as the upstream and downstream bioprocesses. Bio-
therapeutics are usually developed using the so called quality by de-
sign (QbD) approach, where glycosylation is often a very important part
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of the product design as it can enhance such molecular abilities as
increased half-life, specificity and efficacy. Since glycosylation is not
template driven, i.e., not coded in DNA, predicting glycosylation is
very complex and difficult given the number of factors and cellular
processes that must be considered to obtain the desired glycosylation
profile. These factors include the expression levels of relevant glyco-
syltransferase/glycosidase enzymes, the level of monosaccharides and
pseudo-sugars present during fermentation, as well as bioprocessing pa-
rameters, like temperature, pH, O2 and CO2 level, etc.
Thus, comprehensive characterization of all attached N-glycan struc-
tures including positional and linkage information is critical and should
be monitored from early through late stage development to commercial
manufacturing. WHO guidelines on biotherapeutics [8] and the Interna-
tional Conference on Harmonization (ICH) Q6B [9] mandate also stated
that PTMs, such as glycosylation should be identified and adequately de-
termined. Due to the significant impacts of the attached carbohydrate
structures on safety and therapeutic efficacy as discussed above, analysis
of the glycan profiles of therapeutic glycoproteins is an inseparable part
of the quality control strategy for glycosylated biopharmaceuticals.
Since, glycosylation is considered to be critical for quality and it can
be easily influenced by small manufacturing variations or changes, gly-
can related attributes must also be assessed during comparability test-
ing. Consequently, it is also essential for biosimilars to quantitatively
show their resemblance in terms of their glycosylation to the reference
product [10].
Glycan analysis is a challenging task considering the possible high
complexity of these molecules. Their analysis by liquid phase separation
techniques such as liquid chromatography or capillary electrophoresis
is hindered by the lack of chromophore/fluorophore moieties, requir-
ing derivatization, in most cases with fluorescent tags for enhanced de-
tection sensitivity and specificity. For capillary electrophoresis analy-
sis, carbohydrates are labeled by a charged fluorophore to respectively
support their electromigration and sensitive detectability [11]. Rapid
exploratory and structural elucidation of the separated sugars is usu-
ally accomplished by applying the so called glucose unit (GU) value
method, that practically normalizes the migration/elution time of the
separated peaks to an oligosaccharide ladder [12]. The calculated GU
values are then used to search relevant glycan databases (e.g., www.
GlycoStore.org) and the structures of the individual carbohydrates are
suggested/classified with adequate probability. To simplify the calcu-
lation process and increase precision, bracketing or the recently intro-
duced triple internal standard based approach is applied [13]. How-
ever, for exact characterization of the separated gly
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cans, exoglycosidase mediated carbohydrate sequencing and MS analy-
sis are also important [14,15].
Biosimilars, by definition, are copy versions of already authorized
biological medicinal products with demonstrated similarity in physic-
ochemical characteristics, efficacy and safety, based on comprehensive
analytical and clinical similarity studies [16]. Glycosimilarity represents
a substantial subset of biosimilarity [17] and it reflects to similarity in
terms of the glycosylation related critical quality attributes (gCQAs) es-
pecially macro- and micro-heterogeneity. For therapeutic monoclonal
antibodies and Fc fusion proteins these attributes are usually as fol-
lows: afucosylation level (fucosylation affects ADCC function via FCγRIII
binding), total terminal galactosylation (antennary galactosylation in-
fluences CDC activity), total sialylation (terminal sialylation enhances
anti-inflammatory effects), as well as the amount of high mannose struc-
tures and glycan species having terminal GlcNAc (both for their poten-
tial effect on serum half-life). If present, the analysis and quantification
of immunogenic glycan residues are also important parts of such study
focusing on the detection and comparison of the levels of the following
residues: alpha (1,3)galactose, beta (1,2)xylose, alpha (1,3)fucose and
N-glycolylneuraminic acid (Neu5Gc).
2. The glycosimilarity concept
The approach and rules of establishing biosimilarity are defined by
leading regulatory agencies, including but not limited to the US Food
and Drug Administration (FDA) and the European Medicines Agency
(EMA) [18,19]. There are more and more biosimilar candidates have
been granted approvals in recent years with the related documentation
(briefing documents, papers with detailed analytical similarity data sets)
publicly available about their analytical similarity approach and results.
Therefore, the major requirements by the leading agencies nowadays
are considered to be relatively clear across the industry. Both EMA and
FDA recommends the use of a three-tier based approach for the criti-
cality ranking of the different CQAs. Based on this ranking they sug-
gest to use different acceptance criteria/quality ranges to the attrib-
utes considering their importance when assessing similarity between the
reference medicinal product (RMP) and its biosimilar candidates. For
Tier 1 or highly critical attributes the FDA suggests the use of equiva-
lence testing, while EMA recommends the use of quality range (±1.5
SD) with a 95% confidence level. For Tier 2 ranked attributes a qual-
ity range method is suggested by both agencies that is created using
a ± 3 SD upper and lower limit around the RMP mean also with a
95% confidence. In case of the least critical QAs (Tier 3) graphical or
numerical comparison supposed to be sufficient without a predefined
similarity range [18,19]. EMA has also been emphasizing the impor-
tance of testing the reference medicinal product and biosimilar candi-
date samples head-to-head in the same assay using different, preferably
orthogonal analytical methods whenever feasible. Therefore, defining
similarity, or more precisely the glycosimilarity, requires a well-defined
scoring system and rules for comparative characterization such as the
one introduced several decades ago by Altman and Bland for measure
ments in medicine [20]. Recently, their approach was further developed
by Karlsson et al. [21] to be used for similarity comparisons of surface
plasmon resonance sensorgrams to characterize and compare different
protein interactions.
In this tutorial, an efficient and complex similarity scoring system
is presented using a step-by-step approach to define numerical similar-
ity between the N-glycan profile of a model therapeutic monoclonal an-
tibody and an artificially generated spiked test N-glycan pool. The ap-
proach is based on the calculation and combination of two different sim-
ilarity scores. The first one is the profile similarity score, which is cal-
culated by comparing each and every single data points of the normal-
ized electropherogram (or chromatogram) of the test item to a pre-de-
fined quality range that is based on the manufacturing variability of the
reference lot. The second score is the compositional similarity, which is
based on comparing the levels of the different gCQA groups to the sim-
ilarity range that is created just like in the previous case based on the
compositional variations of the released N-glycan pool from 6 different
manufacturing lots. The mean of these two scores results in the final
Glycosimilarity Index (GI). One benefit of using such an index is in com-
plex DoE studies, used for process development and process characteri-
zation activities or during clone selection, the Glycosimilarity Index can
be used as a single response that describes the closeness of the N-glyco-
sylation profile of the test item to the desired target or reference profile.
Using lower number of responses allow the generation of more simpli-
fied, therefore, more accurate and reliable models that eventually lead
better and more robust manufacturing processes. In addition, the use of
the GI is also beneficial in comparability and similarity studies and al-
lows a clear, simple and easy comparison between the two samples and
therefore better decision making. Application of the GI in clone selec-
tion studies enables simple differentiation between the N-glycosylation
profiles of the candidates, while in similarity or comparability studies it
will allow easier comparison between the different manufacturing lots
or the biosimilar candidate and its reference product.
3. Theory
Calculation of the similarity scores is based on the approaches of
Altman and Karlsson [20,21]. Percentage scores are generated with a
simple mathematical calculation for considering all data points (i.e.,
UV absorbance or fluorescence unit values) for the peaks of interest,
falling inside and outside of the Tier pre-defined tolerance limits defined
by ± SD of the mean value from the different reference manufacturing
lots. Points located inside the limits, regardless of their distances from
the mean are scored with 100% similarity as shown in Fig. 1 (first term
in Equation (1)). On the other hand, the contribution of points falling
outside of the tolerance limits are corrected by using a sum of squared
distances to the mean (second term in Equation (1)). Consequently, the
points outside the tolerance limits reduce the similarity score.
Fig. 1. The glycosimilarity scoring concept. UTL: upper tolerance limit, LTL lower tolerance limit.
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(1)
where, Ai represents the percentage of similarity of attribute i (i = 1,
…,n), Yi and Xi represent the percentage of data points inside and out-
side of the tolerance limits of that particular attribute, respectively. The
upper and lower tolerance limits of point j are represented by xuj and xlj,
respectively. The mean of the jth reference material points is , while,
xsj is the jth sample point falling outside the tolerance limits [17] as
shown in Fig. 1. The worked example below details all the calculation
steps for easier understanding.
Linking of the obtained N-glycosylation profile to safety, clearance or
efficacy of the product is usually done through the definition of glycosy-
lation related CQAs (gCQAs). These attributes in most cases are defined
as important subsets of the major N-glycan subtypes, like total afucosy-
lation, total high mannosylation, total sialylation or total terminal galac-
tosylation, etc. Values are assigned to these attributes by summing up
the relative percentage of the amounts of those oligosaccharides having
these terminal sugar residues.
Since the peak area ratio of the different glycans within a gCQA is
also very important, the composition similarity of the released glycan
pool has to be considered as a major attribute. For example, the compo-
sition of the total afucosylation of Fc attached N-glycans is highly critical
in terms of the expected ADCC response. A test mAb with 10% total afu-
cosylation that only comprises of high mannose type glycans will have
significantly different ADCC activity than that of a mAb where the 10%
of afucosylation is a result of mainly complex type N-glycans, like G0,
G1, G1’ or G2. The overall glycosylation similarity (Equation (2)), the
Glycosimilarity Index (GI) is composed of the mean of the profile and
compositional similarity scores (both are calculated by Equation (1))
and the profile similarity is always ranked as a very high criticality (Tier
1) attribute, i.e., on the third power.
(2)
Where n is the number of attributes, Aip is the percent value of the pro-
file similarity score and Aic is the similarity score of attribute i. All sim-
ilarity scores are computed by using Equation (1). ti is the tier rank fac-
tor, which is 3 for high (Tier 1), 2 for moderate (Tier 2) and 1 for attrib-
utes with low criticality (Tier 3). Profile similarity is always a high criti-
cality (tip = 3) attribute, i.e., e3 = 20.09, while the tier factor of compo-
sitional similarity (tic) can range from 1 to 3, i.e., e1 = 2.71, e2 = 7.39
and e3 = 20.09.
In complex molecules containing occupied N-glycosylation sites at
different locations of the molecule such as the fusion protein etaner-
cept with two conserved N-glycosylation sites in its Fc portion and 4
distinct sites on the TNFα receptor part, sub-indexes shall be generated
for each site types with different criticality. Thus, the generation of spe-
cific sub-indexes is required when different type of N-glycosylation sites
are presented with such relevance as surface exposed sites that has no
effect on the primary mechanism of action and conserved Fc sites af-
fecting effector functions or sites that related for half-life and stability.
These glycosylation sites on different parts of the protein therapeutic
normally differ in their glycan composition as well as in the criticality
of their N-glycosylation related attributes such as total sialylation or to-
tal afucosylation. For example, in an Fc fusion protein with significant
effector functions, e.g., ADCC, the afucosylation level is considered to
be a high criticality attribute for the Fc linked oligosaccharides (ti = 3).
On the other hand, for sugars attached to the N-glycosylation sites out-
side of Fc, this attributes have only very low criticality (ti = 1). There-
fore, these sites first have to be grouped based on the primary effect
of their N-glycosylation, and the different groups shall be studied sepa-
rately. When it comes to the calculation of the glycosimilarity index, it
is necessary to calculate different sub-indexes for each groups. In gen
eral terms, lower Glycosimilarity Index implies greater effect of the ob-
served glycosylation differences and consequently weaker overall simi-
larity of a biosimilar candidate.
In practice, the Glycosimilarity Index calculation workflow includes
the following steps:
1) Determination of the target profile by characterizing the reference
lots
2) Identification of the glycosylation related attributes and assessment
of their criticality
3) Classification of gCQAs and definition of their tolerance limits
4) Compositional and profile similarity scoring
5) Calculation of the Glycosimilarity Index
This tutorial provides a step by step approach for calculating the Gly-
cosimilarity Index to obtain a single percentage score that represents
the level of similarity between the different N-glycosylation profiles and
their effect on safety, efficacy and immunogenicity relative to a defined
reference target profile, that is generated from multiple lots of the refer-
ence product.
4. Glycosimilarity index calculation: A worked example
The reference mAb used for this worked example was an isotype
IgG1κ monoclonal antibody expressed in CHO cells with intended tar-
get neutralization (Class II) and plausible ADCC function as part of its
mode of action (MoA). It had only one N-glycosylation site in each heavy
chains of the Fc region of the molecule at Asn297. The N-glycolylneu-
raminic acid (NGNA) content of the product was <0.1% of the total sia-
lylation.
Step 1) Determination of the target profile by characterizing the refer-
ence lots
The released and fluorophore labeled glycans from six different pro-
duction lots of the commercially available reference therapeutic mAb
were analyzed in triplicates by capillary electrophoresis with laser in-
duced fluorescent detection (CE-LIF) in two different sequences in differ-
ent days to obtain the batch-to-batch and analytical variation of both the
electropherogram profile and glycan composition. A representative elec-
tropherogram is shown in Fig. 2 with 15 structures identified based on
their GU values (abbreviated structural names are listed in Table 1, fol-
lowing the Oxford nomenclature as cited in www.glycostore.org). Glu-
cose unit (GU) values were assigned for each data points of the electro-
pherogram by the GUcal software (freely available at www.GUcal.hu)
to accommodate profile similarity calculations. The batch-to-batch peak
area variances of the test mAb N-glycan compositions are depicted in
Table 1.
Step 2) Identification of N-glycosylation related attributes and assess-
ment of their criticality
The type of the biologic and genetic makeup of the host cell line used
in the production of a glycobiotherapeutic drug defines its N-glycosy-
lation attributes and their potential variances. Table 2 lists the abun-
dance of the most important N-linked carbohydrate residues the various
cell lines generate by species. (+++) depicts high abundance, (++)
the presence, while (+) low abundance and (±) both the presence
and absence reported in the literature. Terminal sialylation is an impor-
tant attribute for anti-inflammatory properties, however, the N-glycolyl-
neuraminic acid (Neu5Gc) subtype is immunogenic. Similarly, α1,3-
Galactosylation (α1,3-Gal) and the presence of β1,6-xylose and alpha
α1,3-core fucose are also considered as immunogenic residues. The pres-
ence of oligomannose structures is reportedly responsible for rapid clear-
ance of the mAb from serum, suggesting that these structures are ex-
posed and bind to the mannose receptor expressed by macrophages and
other phagocytic cells [6].
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Fig. 2. N-Glycan profile of the test mAb. Structures of the numbered peaks are listed in Table 1. Conditions are given in the experimental section.
Table 1
Compositional batch-to-batch peak area variations of the test mAb analysis. The lower
panel of the table depicts the percentage distribution of the major glycan subclasses of in-
terest from glycosimilarity point of view.
Peak No. Structure
Lot
#1
Lot
#2
Lot
#3
Lot
#4
Lot
#5
Lot
#6
% % % % % %
1 M3 0.4 0.4 0.3 0.3 0.3 0.4
2 FM3 0.6 0.6 0.3 0.4 0.4 0.3
3 FA1G1S1 0.5 0.5 0.3 0.3 0.3 0.2
4 A2 2.6 2.6 1.9 1.9 2.3 2.2
5 M5 3.5 3.5 2.3 2.3 3.2 2.8
6 FA2G2S1 0.6 0.6 0.3 0.3 0.3 0.2
7 FA2 62.5 62.5 62.4 61.5 66.1 67.3
8 A2[6]G1 2.0 2.0 1.6 1.7 1.8 1.7
9 FA1[6]G1 1.9 1.9 1.3 1.4 1.4 1.5
10 M7 1.8 1.8 1.4 1.5 1.7 1.6
11 FA3 0.5 0.5 0.3 0.3 0.4 0.4
12 FA2[6]G1 14.7 14.7 18.0 18.3 14.2 14.3
13 FA2[3]G1 6.0 6.0 6.8 7.0 5.5 5.4
14 M8 0.5 0.5 0.4 0.4 0.5 0.3
15 FA2G2 1.8 1.8 2.4 2.5 1.6 1.5
100 100 100 100 100 100
Terminal
Gal %
26.4 26.4 30.0 30.8 24.5 24.3
Afucosylated
%
11.0 11.0 8.0 8.1 9.8 9.0
High
mannose%
5.9 5.9 4.3 4.2 5.4 4.7
Sialylation% 1.1 1.1 0.6 0.6 0.6 0.4
Terminal
GlcNAc %
65.6 65.6 64.6 63.7 68.8 69.9
The effects of critical glycan epitope related attributes should be
evaluated based on safety/immunogenicity, biological activity/efficacy
and clearance considerations. Table 3 shows the impact level of the var-
ious mAb sugar residues in view of their criticality. For example, the
α1,3-galactose is highly immunogenic, so (--) reflects its highly negative
impact. The core fucose on the other hand is critical for the biological
activity/efficacy via ADCC function, thus has high impact (++). The
criticality of some sugar epitopes are not yet determined or less impor-
tant reflected by the n.d. (not determined) assignment. Once the criti-
calities of all CQAs are defined, their tolerance window should be de
Table 2
Abundances of N-glycosylation related attributes in different species [22].
N-Glycan attribute CHO BHK NSO, SP2/0 Human Yeast
Sialylation ++ + +++ ++ –
α2,6-sialyl – – + + –
Neu5Gc + +++ +++ +/−* –
α1,3-Gal – + ++ – –
bisect. GlcNAc – – – + –
α1,6-core Fuc + + ++ + –
α1,3-core Fuc – – – – –
β1,6-xylose – – – – –
High-mannose + + + + +++
CHO: Chinese hamster ovary; BHK: baby hamster kidney; NS0: nonsecreting murine
myeloma; SP2: mouse hybridoma cells. +++ abundant presence ++ presence + low
presence – not present ± both, presence and absence reported, *possible presence of
Neu5Gc from exogenous sources.
Table 3
Effects of Fc glycosylation on mAb product quality (PK: pharmacokinetics; PD: pharmaco-
dynamics [23,24].
N-Glycan
attribute Safety/Immunogenicity
Biological
activity
Clearance (PK/
PD)
Term. Galactose n.d. + -
Term. GlcNAc n.d. - -
α1,3-Gal – n.d. n.d.
Core Fucose n.d. ++ n.d.
bisect. GlcNAc n.d. + n.d.
High-mannose n.d. + –
Neu5Gc – (−) +
Sialylation n.d. (−) +
α1,3-core Fuc – n.d. n.d.
β1,6-xylose – n.d. n.d.
+ positive impact; ++ high positive impact; - negative impact; -- high negative impact;
(±) potential impact.
fined.
Step 3) Classification of gCQAs and definition of their tolerance limits
In this exercise, a three Tier based criticality assessment of quality
attributes were used. Classification of the different glycosylation related
attributes were based on the abundance and effect of the certain gly
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can types to pre-defined mechanisms of action and on their contribu-
tion to the safety and clearance profile of the reference mAb. Tier 1
(high) includes gCQAs that are directly impacting the potency of the
product, in this instance the ADCC function (level of core fucosylation)
and clearance (high mannose structures). This required to fall within the
mean ± 1.5 SD of the multiple reference product batches tested. Attrib-
utes ranked as Tier 2 has moderate impact on product quality, so the
tolerance limits for these attributes are calculated as mean ± 3.0 SD. Fi-
nally, glycan types with low or no significant impact at these abundance
levels are controlled by fix upper limits at the compositional level and
mean ± 3.0 SD tolerance limit for profile similarity calculation.
Based on the three Tier information, the tolerance limits used for the
critical sugar residues for the test mAb are shown in Table 4. As one can
observe, the N-glycan attribute criticality of the total afucosylated (i.e.,
non-core fucosylated) structures are high, thus have ±1.5 SD tolerance
limit for both profile and compositional similarity. It is important to note
that total afucosylation also includes other structures without core fu-
cose, e.g., high mannose structures. Actually, in profile similarity assess-
ment the ±1.5 SD tolerance limit should apply for the high mannose
structure subset anyway, considering its important role in clearance.
First, the relative fluorescence intensities (RFU) of the peaks were
normalized based on the highest peak in the electropherogram to min-
imize the effects of analytical variability on the calculated similarity
score. GU ranges used in similarity calculation were defined based on
peak integration and the ranges were set according to peak start/end
points. The glycosylation related N-glycan attributes, their criticalities
and the corresponding tolerance limits for the test mAb are listed in
Table 5. In case a particular glycan could be considered in two different
attribute groups with different criticality, the stricter limits were applied
during score calculation. For example, for the total amount of afucosy-
lated structures the sum of structures without core fucose included high
mannose structures. Therefore, in profile similarity assessment the ±1.5
SD tolerance limit was applied for high mannose structures too for this
subset. The Mean as well as the Upper and Lower Tolerance limits were
calculated using the normalized RFUs of the 6 different reference lots,
point-by-point. Data points in the electropherograms outside of the as-
sessed GU ranges (i.e., baseline) were considered in the similarity score
calculation with a ±6.0 SD tolerance limit.
Step 4) Compositional and profile similarity scoring
To better demonstrate the Glycosimilarity Index calculation work-
flow, two artificial N-glycan profiles were generated by spiking the re-
leased and APTS labeled test mAb N-glycan pool with 1 and 2 pmol
of both APTS labeled Man5 and FA2G2 glycan standards, referred to
as Model 1 and Model 2, respectively. These models represent increase
in the amounts of core fucosylated and high mannose structures,
Table 4
Glycosylation related critical quality attributes (gCQA) and their tolerance limits.
gCQA
N-glycan
Attribute
criticality
Tolerance limit for
profile similarity
Tolerance limit for
compositional similarity
Terminal
Gal %
Moderate (Tier
2)
±3 SD ±3 SD
Total
afucosylated
%
High (Tier 1) ±1.5 SD ±1.5 SD
High
mannose %
High (Tier 1) ±1.5 SD ±1.5 SD
Sialylation
%
Low (Tier 3) ±3 SD <3%
Terminal
GlcNAc %
Low (Tier 3) ±3 SD ±3 SD
Table 5
GU ranges of the individual structures with their tolerance limits.
Peak No. Structure GU range of peaks Tolerance limit
1 M3 6.31–6.75 ±1.5 SD
2 FM3 6.76–6.89 ±3.0 SD
3 FA1G1S1 6.92–7.04 ±3.0 SD
4 A2 (G0) 7.68–7.77 ±1.5 SD
5 M5 7.77–7.85 ±1.5 SD
6 FA2G2S1 7.95–8.44 ±3.0 SD
7 FA2 (G0F) 8.58–8.75 ±3.0 SD
8 A2 [6]G1 8.84–8.99 ±1.5 SD
9 FA1 [6]G1 9.13–9.28 ±3.0 SD
10 M7 9.32–9.53 ±1.5 SD
11 FA3 9.57–9.64 ±3.0 SD
12 FA2 [6]G1 (G1F) 9.65–9.82 ±3.0 SD
13 FA2 [3]G1 (G1'F) 9.95–10.17 ±3.0 SD
14 M8 10.55–10.66 ±1.5 SD
15 FA2G2 (G2F) 11.03–11.18 ±3.0 SD
i.e., change the amounts of these two gCQAs. Fig. 3, panel A shows
the superimposed CE-LIF traces of the mean profile of the six mAb lots
with the spiked glycan pools with 1 and 2 pmol of Man5 and FA2G2 for
Model 1 and Model 2, respectively. Panel B depicts the blown-up part of
peaks 8–10. As one can observe in Panel A, the sizes of those two spiked
peaks increased, while the area of the rest of the peaks remained prac-
tically unchanged. More importantly, the added amounts of these two
glycans increased the corresponding peak sizes beyond the upper toler-
ance limits, consequently resulting in decreased glycosimilarity.
Compositional similarity scores were calculated by Equation (1) us-
ing the concept delineated in Fig. 1. Table 6 depicts the N-glycosyla-
tion attributes of the major glycan subtypes of Terminal Gal %, Total
afucosylated %, High mannose %, Sialylation % and Terminal GlcNAc
% for the mean of the 6 lots, as well as for the two Model mixtures. The
compositions were calculated for Model 1 spiked by 1 pmol and Model
2 spiked by 2 pmols of FA2G2 and Man5, each. As an example, the limit
distance for the Tier 1 gCQA total afucosylated structures (second line
in Table 6) with the mean value of 9.5 were LD = 2.0, thus, the lower
tolerance limit (LTL) was 9.5–2 = 7.5; while the upper tolerance limit
(UTL) was 9.5 + 2 = 11.5. After spiking with 1 pmol Man5 and FA2G2,
the mean increased from 9.5 to 14.5, with the corresponding differences
of 5 units. Considering the 2-unit limit distance (LD), the compositional
similarity (CS) % score for this attribute was calculated based on Equa-
tion (1) as follows: 100 x (22/52) = 16.3, where 2 is the limit distance
and 5 is the actual distance from the mean. The compositional similarity
scores for the four other attributes were calculated similarly, considering
100% when the data points fell within the LTL and UTL and using the
calculation scheme above for the other ones when the data points fell
outside of the LTL and UTL. For the rest of the subtypes, this calculation
resulted in 100% for Terminal Gal%, 23.8% for High Mannose, 100% for
Sialylation and 86.7% for Terminal GlcNAc N-glycosylation attributes.
In profile similarity calculation, the three small peaks highlighted by
the gray box in Fig. 3 (in the GU range of 8.58–9.65) were first as-
sessed among the traces. Panel B in Fig. 3 depicts the blown up su-
perimposed traces of the separation of the 6 test mAb lots for the in-
dividual peaks of 8, 9 and 10 with the median (dotted line) and the
upper and lower tolerance limits (dashed lines) as defined in Table 5.
The corresponding structures for these peaks were 8: A2 [6]G1 (ter-
minal galactosylated afucosylated), 9: FA1 [6]G1 (terminal galactosy-
lated fucosylated) and 10: M7 (high mannose) structures, all within
the predefined tolerance limits of ±1.5, ±3.0 and ± 1.5, respectively.
Therefore, considering each and every single data points of these peaks,
based on the scheme of Fig. 1, all fell within the predefined toler-
ance limits. The corresponding calculation by Equation (1) resulted in
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Fig. 3. Superimposed electropherograms (panel A) of the released and APTS labeled six mAb lots (black trace) with the spiked glycan pools containing 1 and 2 pmol of M5 and FA2G2 for
Model 1 (red trace) and Model 2 (blue trace), respectively. Panel B depicts the blown-up part of peaks 8–10 with the black dotted and the red dotted lines representing the mean as well
as the upper and lower tolerance limits, respectively. The other color traces correspond to the 6 production batches analyzed in the study.
Table 6
Calculated compositional Similarity (CS) score values.
N-glycosylation attributes Mean SD LTL UTL LD Model 1 CS% score Model 1 Model 2 CS% score Model 2
Terminal Gal % 27.1 2.7 18.8 35.3 8.1 (3SD) 30.1 100 33.5 100
Total afucosylated % 9.5 1.3 7.5 11.5 2.0 (1.5SD) 14.5 16.3 17.2 6.8
High mannose % 5 0.8 2.7 7.4 1.2 (1.5SD) 9.9 23.8 13.1 8.7
Sialylation % 0.7 0.3 0 1.6 0.9 (3SD) 0.7 100 0.6 100
Terminal GlcNAc % 66.4 2.5 59 73.7 7.5 (3SD) 58.5 86.7 52.1 26.8
100% profile similarity scores for these peaks, as the first term was
100% (all data points were inside the tolerance limits) and the second
term was zero (no data points were outside of the tolerance limits). The
same was true for all other features within the tolerance limits, i.e., for
peaks 1–4, 6,7 and 11–14. Profile similarities were calculated for each
and every single data points the same way for the spiked peaks of 5
(Man 5) and 15 (FA2G2). As one can see in Fig. 3 the Man 5 (peak 5)
and FA2G2 (peak 15) peaks of both spiked traces exceeded the upper
tolerance limit, thus, the second term of Equation (1) kicked in and de-
creased the profile similarity scores for Model 1 and Model 2, to 84.2%
and 80.2% respectively.
Step 5) Calculation of the Glycosimilarity Index
The Glycosimilarity Index was then calculated by using Equation (2),
taking in account of the profile and compositional similarity scores cal-
culated above. The corresponding numbers for Worked Example Model
1 in Equation (2) were as follows:
where = 2.713 = 20.09, Aip is the percent value of the profile simi-
larity score (84.2), and Aic is the similarity score of the predefined attrib-
utes of Terminal Gal % (e2 x 100%), Total afucosylated %, (e3 x 16.3%)
High mannose % (e2 x 23.8%), Sialylation % (e1 x 100%) and Terminal
GlcNAc % (e1 x 86.7%). All similarity scores were computed by Equa-
tion (1). Similar calculation for Model 2 resulted in GIModel 2 = 41.12%.
5. Discussion
The Glycosimilarity Index gives a percentage score on the similar-
ity of the N-glycosylation patterns in comparability and/or biosimilar
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ity studies of glycosylated therapeutic proteins. The use of this approach
makes comparisons easily quantifiable in manufacturing between pre-
and post-change batches or between the innovator and their biosimi-
lar counterparts. This type of similarity scoring can also be used in sys-
tem suitability testing when criteria such as “comparable/similar to ref-
erence standard” is used, allowing the specification of exact and objec-
tive numerical limits instead of subjective comparisons by the analysts.
Using profile similarity scoring only can be a good approach to assess
system suitability in N-glycan profiling assays by calculating and com-
paring exact values when assessing the comparable/similar to reference
standard criteria. Please note that the type of the biologic and genetic
makeup of the host cell line as well as the developed manufacturing
process defines the N-glycosylation attributes and their potential vari-
ances. In the Worked Example of this study, only well-defined and char-
acterized profiles were compared with relatively small variances for eas-
ier demonstration of the workflow. Based on the calculated composi-
tional and profile similarity scores, the Glycosimilarity Index for Models
1 and 2 were 51.21% and 41.12%, respectively, both falling well below
80% [17], thus, exhibiting weak similarity in their N-linked glycan pro-
files, suggesting that the generated models would have significant differ-
ences in their Fc mediated functions and/or their contribution to clear-
ance.
The Glycosimilarity Index (GI) also holds the potential to simplify
and facilitate decision making for the biopharmaceutical industry during
clone selection or process development studies representing all glycosy-
lation profile changes with a single score. This makes the application of
the Glycosimilarity Index extremely beneficial in design of experiment
(DoE) models, where glycosylation changes can be defined as a single
outcome only. This simplifies the models without the loss of important
information and allows to create more robust and reduced dimensional
design spaces.
6. Experimental
6.1. Chemicals and reagents
The Fast Glycan Sample Preparation and Analysis kit was from Sciex
(Brea, CA). APTS labeled oligomannose 5 (Man5) and asialo-, galac-
tosylated biantennary complex N-glycan, core-substituted with fucose
(FA2G2) were from Prozyme (Hayward, CA). The PNGase F enzyme was
from Asparia Glycomics (San Sebastian, Spain). The sodium cyanoboro-
hydride (1 M, in THF) and all other chemicals were obtained from
Sigma-Aldrich (St Louis, MO).
6.2. Reference mAb and sample preparation
Six batches of the test monoclonal antibody (Isotype IgG1κ) ex-
pressed in CHO cells with the intended mode of action of Class II (target
neutralization) with plausible ADCC function were subject to glycosimi-
larity scoring in the Worked Example. The test mAb had only one N-gly-
cosylation site at the conserved Asn297 on the Fc region of the molecule
in both of the heavy chains. The N-glycolylneuraminic acid (NGNA) con-
tent of the product was <0.1% of total sialylation. Sample preparation
followed the protocol of the Fast Glycan Analysis kit of Sciex. Models 1
and 2 were spiked pools of the 6 batches by the addition of 1 and 2 pmol
of both Man5 and FA2G2 glycans, respectively. In all experiments the
Fast Glycan Sample Preparation and Analysis kit was used with the re-
spective reagent/buffer compositions and CE separation parameters.
6.3. CE-LIF analysis
In all separation experiments a PA 800 Plus Pharmaceutical Analy-
sis System (Sciex) with laser induced fluorescent detection (λex = 488
nm / λem = 520 nm) was used with 50 μm internal diameter (365 μm
outside diameter) bare fused-silica capillary column (effective length:
50 cm, total length: 60 cm). The applied electric field strength
was 500 V/cm in reversed polarity mode (cathode at the injection side)
at 30 °C separation temperature. A water pre-injection by 3.0 psi for
5.0 s was followed by the injection of the sample (2.0 kV for 2.0 s)
and the bracketing standard mixture of maltose and maltopentadecaose
(1.0 kV for 1.0 s). For data acquisition and processing, the 32 Karat soft-
ware, version 10.1 (Sciex) was used. Glucose unit values were deter-
mined by the freely available GUcal software (www.GUcal.hu).
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